Sign in Subscribe
United States. Securities and Exchange Commission

Boston Scientific Corp. Submits SEC Filing, Reports Fiscal Quarter Results

Strategic Insights

— 1 min read

Boston Scientific Corp. has recently submitted a U.S. Securities and Exchange Commission (SEC) filing, detailing its financial performance for the first fiscal quarter of the year. The company, a leading developer and manufacturer of minimally invasive medical devices, provided an unaudited financial statement in the Form 10-Q filing. The report outlines the company's financial position during the quarter, offering insights into its continued growth in the biotechnology sector.

Key Takeaways:

  • The SEC filing (Form 10-Q) contains unaudited financial statements for the first fiscal quarter of Boston Scientific Corp.
  • The company is required to file quarterly reports, with each report due within 45 days of the close of the quarter.
  • Boston Scientific Corp. operates in the biotechnology sector, specifically in the development and manufacturing of minimally invasive medical devices.
  • The company's financial performance during the first fiscal quarter is detailed in the SEC filing, providing stakeholders with a comprehensive view of the company's financial position.
  • The company has a contact address of 300 Boston Scientific Way, Marlborough, MA 01752-1234, and a phone number of 508-683-4000.
  • The SEC filing #0000885725-15-000012 contains 17 supporting documents, as per the U.S. Securities and Exchange Commission's requirements.

Statistics:

  • The SEC filing #0000885725-15-000012 contains 17 supporting documents.
  • The company's financial performance is detailed in the Form 10-Q filing, which serves as a continuing view of the company's financial position during the year.

Sources:

  • Boston Scientific Corp. SEC filing #0000885725-15-000012 (Form 10-Q), May 6, 2015
  • U.S. Securities and Exchange Commission (SEC), http://www.sec.gov/Archives/edgar/data/885725/0000885725-15-000012-index.html

Read more